ECE2016 Guided Posters Cardiovascular endocrinology (9 abstracts)
IGF-1: A marker of cardio-metabolic risk in obstructive sleep apnea (OSA) syndrome?
JL Pépin 1 , LM Galerneau 1 , AL Borel 2 , O Chabre 2 , M Sapene 3 , B Stach 4 , J Girey-Rannaud 5 , R Tamisier 1 & Ph Caron 6
1EFCR et du Sommeil, Grenoble, France; 2Service d’Endocrinologie, CHU, Grenoble, France; 3Centre de Pneumologie Rivière, Bordeaux, France; 4Clinique Tessier, Valenciennes, France; 5Cabinet de Pneumologie, Grenoble, France; 6Service d’Endocrinologie, CHU Larrey, Toulouse, France.
Introduction: Insulin-like growth factor-1 (IGF-I), the main growth factor associated with GH secretion, directly opposes endothelial dysfunction and limit early atherosclerosis by favoring nitric oxide production, promoting insulin sensitivity and preventing postprandial dyslipidemia. A low serum IGF-I level has been reported in patients with OSA syndrome and might be one of the mechanisms underlying cardio-metabolic risks in OSA patients. IGF-1 levels were evaluated in a large prospective cohort of patients referred for suspicion of OSA syndrome.
Patients and Methods: In a multicenter national study, 817 patients consulting for suspicion of OSA had serum IGF-1 measurements and OSA syndrome was confirmed in 567 patients by polysomnography or respiratory polygraphy. We analyzed the association between serum IGF-1 below the median value of the population with variables related to cardio-metabolic risks, like body mass index (BMI), apnea hypopnea index (AHI), cholesterol and triglycerides levels (expressed in quartile, median or continuous variables).
Results: Median IGF-1 median was 138 ng/ml. For the whole population (n=817) and after adjustment for age and gender, an IGF-1 below the median was associated with increased BMI (OR =2.83; P<0.0001), AHI (OR =3.03, P<0.0001 for Quartile 4 vs 1), cholesterol (OR=1.36, P=0.0444), and triglycerides (OR=1.36; P=0.0008) levels, respectively. In patients with OSA syndrome (n=567), IGF-1 level below the median value was also associated with increased BMI (OR =2.03, P<0.0069), AHI (OR=3.03, P<0.0001 for Quartile 4 vs 1), and elevated triglyceride levels (OR=1.29; P=0.0152).
Conclusion: In patients with OSA syndrome low IGF-1 levels are associated with recognized predictors of cardio-metabolic risks. So, IGF-1 has potentially a role as a prognosis biomarker in OSA patients and our results also provide insights regarding possible mechanisms of co-morbidities in such patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more